In other meta-analyses of cardiovascular outcome trials involving newer antihyperglycemic medications (such as dipeptidyl-peptidase-4 inhibitors [DPP-4i], glucagon-like peptide-1 receptor agonists [GLP-1RA], and sodium-glucose cotransporter-2 inhibitors [SGLT2i]), significant associations were observed between improvements in glycemic control and the reduction of MACE risk [4–7], whereas no association was identified between glycemic improvement and the risk of HF [5–7]. This evidence concerns the gene SLC5A2 and hydrops fetalis.